FDA-approved agents include liraglutide, semaglutide, tirzepatide, and orforglipron, and a number of emerging therapies are currently in the pipeline
Neuroprotective Effect of GLP-1RAs Cognitive dysfunction is a neurodegenerative disorder that impairs multiple cognitive domains, including memory, language, executive function, and spatial orientation, with the extent of impairment correlating with disease severity
Some had hoped that its efficacy would more closely resemble that of existing injections on the market which can result in up to a 20% body weight loss while others noted the trial drop-out rate of 12% due to side effects or personal reasons
To fully comprehend the advantages and possible consequences of Tirzepatide blood sugar impact, we must understand how this drug interacts with one's glycemic status
International Psycogeriatrics, 2012